Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HemodyNoOc: Octreotide and Norepinephrine in Cirrhotic Hemorrhagic Shock
NCT03891849Withdrawn
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of octreotide in hemorrhagic shock and Variceal hemorrhage (VH), sponsored by CHU Amiens-Picardie. Primary endpoint: Change from baseline of microcirculatory flow index at 24 hours. Planned start Sep 2021; status: withdrawn.
02
Drugs
octreotide
03
Conditions
hemorrhagic shockVariceal hemorrhage (VH)
Beyond the preview
Go deeper on NCT03891849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891849.